Does TRASTUZUMAB DERUXTECAN Cause Malignant neoplasm progression? 171 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 171 reports of Malignant neoplasm progression have been filed in association with TRASTUZUMAB DERUXTECAN (Enhertu). This represents 6.4% of all adverse event reports for TRASTUZUMAB DERUXTECAN.
171
Reports of Malignant neoplasm progression with TRASTUZUMAB DERUXTECAN
6.4%
of all TRASTUZUMAB DERUXTECAN reports
48
Deaths
29
Hospitalizations
How Dangerous Is Malignant neoplasm progression From TRASTUZUMAB DERUXTECAN?
Of the 171 reports, 48 (28.1%) resulted in death, 29 (17.0%) required hospitalization, and 7 (4.1%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TRASTUZUMAB DERUXTECAN. However, 171 reports have been filed with the FAERS database.
What Other Side Effects Does TRASTUZUMAB DERUXTECAN Cause?
Death (384)
Off label use (258)
Nausea (251)
Myelosuppression (242)
Fatigue (186)
Vomiting (140)
Diarrhoea (132)
Interstitial lung disease (130)
Pneumonitis (125)
Metastases to central nervous system (103)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which TRASTUZUMAB DERUXTECAN Alternatives Have Lower Malignant neoplasm progression Risk?
TRASTUZUMAB DERUXTECAN vs TRASTUZUMAB-DKST
TRASTUZUMAB DERUXTECAN vs TRASTUZUMAB-DTTB
TRASTUZUMAB DERUXTECAN vs TRASTUZUMAB EMTANSINE
TRASTUZUMAB DERUXTECAN vs TRASTUZUMAB-PKRB
TRASTUZUMAB DERUXTECAN vs TRASTUZUMAB-QYYP